PD-1/PD-L1 inhibitors have shown efficacy in a variety of cancers, and the combination of platinum-based chemotherapy and PD-1/PD-L1 inhibitors is gradually becoming a focus of attention (Liu et al., 2023; Ren et al., 2023). This evidence concerns the gene PDCD1 and cancer.